RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.

RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.